InterPAD - DETAILS

2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-1,3(2H,9bH)-dibenzofurandione, usnic acid

No.	Title	Href
1	Effect-enhancing and toxicity-reducing activity of usnic acid in ascitic tumor-bearing mice treated with bleomycin. Int Immunopharmacol. 2017 May;46:146-155. doi: 10.1016/j.intimp.2017.03.004.	`Click`
2	Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid. J Pharm Pharmacol. 2019 Jul;71(7):1119-1132. doi: 10.1111/jphp.13097.	`Click`

No.

Title

Href

Effect-enhancing and toxicity-reducing activity of usnic acid in ascitic tumor-bearing mice treated with bleomycin. Int Immunopharmacol. 2017 May;46:146-155. doi: 10.1016/j.intimp.2017.03.004.

Click

Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid. J Pharm Pharmacol. 2019 Jul;71(7):1119-1132. doi: 10.1111/jphp.13097.

Click

Name	Usnic acid
PubChem CID	5646
Molecular Weight	344.3g/mol
Synonyms	2,6-diacetyl-7,9-dihydroxy-8,9b-dimethyl-1,3(2H,9bH)-dibenzofurandione, usnic acid
Formula	C₁₈H₁₆O₇
SMILES	CC1=C(C(=C2C(=C1O)C3(C(=CC(=O)C(C3=O)C(=O)C)O2)C)C(=O)C)O
InChI	1S/C18H16O7/c1-6-14(22)12(8(3)20)16-13(15(6)23)18(4)10(25-16)5-9(21)11(7(2)19)17(18)24/h5,11,22-23H,1-4H3
InChIKey	CUCUKLJLRRAKFN-UHFFFAOYSA-N
CAS Number	125-46-2
ChEMBL ID	CHEMBL1375951
ChEBI ID	CHEBI:2264
Toxicity	Organism	Test Type	Route(Dose)
	rat	LD50	intraperitoneal(165 mg/kg)
	mouse	LD50	intraperitoneal(254 mg/kg)
	rat	LD50	oral(322 mg/kg)
Structure			Download 2D MOL 3D MOL

Chineses Pinyin	GuiJianYu
Use Part	Stem
Habitat	China
Flavor	Bitter
Meridian Tropism	Liver, Spleen

Chineses Pinyin	SongLuo
Use Part	Filament
Habitat	HeiLongJiang, JiLin, NeiMengGu, Shaanxi, GanSu, ZheJiang, FuJian, TaiWan, SiChuan, YunNan, LiaoNing, ShanXi, AnHui, JiangXi
Species	>Kingdom: Viridiplantae 　-->Phylum: Lichenes 　　-->Class: Ascolichenes 　　　　-->Family: Usneaceae 　　　　　-->Genus: Usnea 　　　　　　-->Species: Usnea diffracta

Pair Name	Usnic acid, Sorafenib
Partner Name	Sorafenib
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Down-regulation	Expression	MAP2K3	hsa5606
	Down-regulation	Expression	MAPK1	hsa5594
	Down-regulation	Expression	MAPK3	hsa5595
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
In Vitro Model	SNU-449	Adult hepatocellular carcinoma	Homo sapiens (Human)	CVCL_0454
Result	Investigation of new treatment option for hepatocellular carcinoma: a combination of sorafenib with usnic acid

Pair Name	Usnic acid, Bleomycin
Partner Name	Bleomycin
Disease Info	[ICD-11: 2F94]	Ascitic tumor		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G0/G1 phase
Gene Regulation	Up-regulation	Cleavage	CASP3	hsa836
	Up-regulation	Cleavage	CASP8	hsa841
	Down-regulation	Expression	CCND1	hsa595
	Down-regulation	Expression	CCNE1	hsa898
	Up-regulation	Expression	CDKN1A	hsa1026
	Up-regulation	Expression	IL1B	hsa3553
	Up-regulation	Expression	IL6	hsa3569
	Up-regulation	Expression	PHEX	hsa5251
	Down-regulation	Expression	SMAD2	hsa4087
	Up-regulation	Expression	SMAD3	hsa4088
	Up-regulation	Expression	SMAD7	hsa4092
	Down-regulation	Expression	SOD1	hsa6647
	Up-regulation	Expression	TGFB1	hsa7040
	Up-regulation	Expression	TNF	hsa7124
	Up-regulation	Expression	TP53	hsa7157
In Vitro Model	H22	Hepatocellular carcinoma	Mus musculus (Mouse)	CVCL_H613
In Vivo Model	Mice in Model, BLM, UA and UA + BLM groups were inoculated with H22 cells (0.2 mL, 2×10⁶ cells/mouse, i.p.) to establish malignant ascites tumor-bearing mouse model.
Result	Effect-enhancing and toxicity-reducing activity of usnic acid in ascitic tumor-bearing mice treated with bleomycin